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disease confirmed by a biochemical and molecular genetic ex-
aminations (1).
So far, ERT has been generally prescribed to patients with 
motor symptoms (muscle weakness) and/or respiratory involve-
ment.
Exclusion criteria encompassed a severe associated illness 
which would be expected to greatly shorten life expectancy. 
Alglucosidase (Myozyme) is administered biweekly i.v. as 
20 mg/kg. Although the high costs of the drug, in several Euro-
pean countries the patients are fully supported by their Minis-
tries of Health. 
In fact, in Belgium, National guidelines consider every pa-
tient with clinical symptoms of muscle and/or respiratory in-
volvement as a candidate for ERT that, on the other hand, should 
not be started in patients showing neither a clinical impact of the 
disease or with a limited life expectancy.
In the Netherlands, the inclusion criteria are the confirma-
tion of diagnosis via enzyme assay and mutation analysis, and 
patients should have demonstrable muscle weakness and/or pul-
monary function < 80%.
In UK, specific guidelines, prepared by a multidisciplinary 
group (2007), included patients with muscle weakness and/or 
respiratory compromise leading to an impaired quality of life as 
candidate for treatment. 
In  France,  Pompe  disease  experts  recommend  to  treat 
symptomatic patients (muscle weakness and/or respiratory in-
volvement - FVC < 80%). 
In Germany and in Poland there is a generic recommenda-
tion to treat symptomatic patients. 
In addition, in Brazil there is a recommendation to treat 
symptomatic patients; mild cases have to be progressively fol-
lowed by respiratory and /or muscular functional tests and/or by 
muscle MRI before starting ERT. 
Because  of  the  high  costs  of  ERT,  in  several  countries 
Health authorities (and EMA in Europe) request precise data 
concerning the clinical effects and safety of ERT to reimburse 
the treatment.
Given the data obtained in different cohorts of patients, 
treated with ERT, there is a clear evidence that alglucosidase 
improves  the  walking  distance  and  stabilizes  the  pulmonary 
function. A precise monitoring should help to make a decision 
for initiating or even interrupt ERT
Patients should be followed in specialized neuromuscular or 
metabolic Departments, in connection with a pulmonology unit.
Follow-up visits should be organized every 6 months or 
once a year with clinical evaluations performed by expert physi-
cians and trained physiotherapists; those results should be col-
lected on dedicated data base/registries.
To date, there is a need of specific outcome measures to 
monitor patients before treatment and during the follow up.
Across various European countries and US, clinical assess-
ment has been differentially monitored. In fact 6 MWT, MMT, 
MFM scale, timed tests (i.e. GSGC), WGMS, muscle MRI, SF-
36, have been applied every 3-6 months/1 year to patients. 
Since  2006,  AIFA  (Agenzia  Italiana  del  Farmaco)  has 
approved alglucosidase alfa (Myozyme) for the treatment of 
Pompe disease patients in Italy, either for infantile or late-onset 
patients. 
eters that must be carefully considered to monitor the clinical 
picture and the response to treatment. Calculation of the body 
mass index (BMI), plicometry and waistline measurement are 
useful evaluations, but they are not enough for the study of fat 
and muscle mass. To this end, bodily bioimpedentiometry (BIA) 
is a system of enquiry more frequently used. Pompe disease is 
a cronic, progressive, and crippling disease, so an appropriate 
lifestyle is necessary, which can be obtained by learning how to 
self-manage the disease. Dietary advice is not enough: a biopsy-
chopedagogic  approach,  based  on  an  empathetic  relationship 
between patient and medical team, is necessary.
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Pompe disease is a rare lysosomal disorder of muscle gly-
cogen metabolism due to alfa-glucosidase (GAA) deficiency. 
The prevalence of this disease is estimated to be 1:40.000. 
Since 2006, Enzyme Replacement Therapy (ERT) became 
available in Europe and US. So far, there are no officially ap-
proved  international  guidelines  about  ERT  inclusion  criteria 
of patients but they must have a defined diagnosis of Pompe 210
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(the only available biomarker of muscle glycogenosis type II) 
and brain MRI if there are symptoms suggestive of CNS in-
volvement.
In conclusion, being available the ERT therapy, it is really 
important to diagnose Pompe disease as soon as possible to 
avoid respiratory and skeletal muscle degeneration. 
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Not arrived
The authorisation to treat patients by ERT has to be given 
by Centres specialized in rare diseases. Every Centre must as-
sess the diagnosis of Pompe disease with absolute certainty be-
fore starting treatment. 
In 2008, a group of Italian Pompe disease experts reviewed, 
from a multidisciplinary point of view, the current practices in 
diagnosis, management and treatment of Pompe disease (2). 
The main criteria for starting ERT included: 1) confirmed di-
agnosis; 2) symptoms and clinical signs of muscle weakness 
and or respiratory insufficiency; 3) in cases of asymptomatic 
hyperckemia, a 6-months follow up was suggested in an attempt 
to monitor clinically relevant changes leading to treatment. 
The standard protocol mainly includes evaluation of mus-
cle strength, respiratory assessment and skeletal muscle MRI 
that has been applied to 74 patients treated with ERT coming 
from 18 different Italian Centres, recently described by Angelini 
et al. (3). 
Nowadays, general recommendations includes monitoring 
of limb muscles and respiratory functions every 6 months using 
timed tests and functional scales. Muscle MRI may constitute 
an important tool to check the progression of intramuscular fat 
replacement in the patients (4). 
Respiratory function should include at least assessment of 
upright and supine FVC. Other important aspects of the disease 
to be considered are the cardiac function (ECG once a year) as 
well as antiRhGAA antibodies (every 3 months) levels, Glc4 